Importer of Controlled Substances; Notice of Registration, 55585-55586 [E9-25908]
Download as PDF
<![CDATA[
55585
Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Notices
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than November 27, 2009.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
(40 FR 43745–46), all applicants for
registration to import a basic class of
any controlled substance listed in
schedule I or II are, and will continue
to be, required to demonstrate to the
Deputy Assistant Administrator, Office
of Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: October 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–26001 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
commercial distribution. No other use of
the imported material in question will
be allowed.
DEA has considered the factors in 21
U.S.C. 823(a) and § 952(a) and
determined that the registration of
Mylan Pharmaceuticals Inc., to import
the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Mylan Pharmaceuticals Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: October 16, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–25888 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
Importer of Controlled Substances;
Notice of Registration
By Notice dated June 3, 2009, and
published in the Federal Register on
June 9, 2009 (74 FR 27349), Mylan
Pharmaceuticals Inc., 781 Chestnut
Ridge Road, Morgantown, West Virginia
26505, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
the basic classes of controlled
substances listed in schedule II:
Drug
Schedule
erowe on DSK5CLS3C1PROD with NOTICES
Methylphenidate (1724) ................
Fentanyl (9801) .............................
II
II
The company plans to import the
listed controlled substances for
analytical research and clinical trials.
Two objections and one request for a
hearing were received. The request for
a hearing has been withdrawn. DEA has
examined the other objections to the
registration and has determined that the
objections and comments received are
not valid for this specific situation. The
company will import finished dosage
forms for clinical trials and analytical
comparison only. They will not
purchase raw material for the
manufacture of finished goods and/or
VerDate Nov<24>2008
15:34 Oct 27, 2009
Jkt 220001
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: October 20, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–25891 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated June 3, 2009, and
published in the Federal Register on
June 9, 2009 (74 FR 27349), Mylan
Technologies Inc., 110 Lake Street, Saint
Albans, Vermont 05478, made
application to the Drug Enforcement
Administration (DEA) to be registered as
an importer of the basic classes of
controlled substances listed in schedule
II:
DEPARTMENT OF JUSTICE
Drug
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated April 17, 2009, and
published in the Federal Register on
April 29, 2009, (74 FR 19598),
Archimica, Inc., 2460 W. Bennett Street,
Springfield, Missouri 65807–1229, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Lisdexamfetamine (1205), a basic class
of controlled substance listed in
schedule II.
The company plans to manufacture
the controlled substance in bulk for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Archimica, Inc. to manufacture the
listed basic classes of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Archimica, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
PO 00000
Frm 00050
Fmt 4703
Sfmt 4703
Methylphenidate (1724) ................
Fentanyl (9801) .............................
Schedule
II
II
The company plans to import the
listed controlled substances for
analytical research and clinical trials.
Two objections and one request for a
hearing were received. The request for
a hearing has been withdrawn. DEA has
examined the other objections to the
registration and has determined that the
objections and comments received are
not valid for this specific situation. The
company will import finished dosage
forms for clinical trials and analytical
comparison only. They will not
purchase raw material for the
manufacture of finished goods and/or
commercial distribution. No other use of
the imported material in question will
be allowed.
DEA has considered the factors in 21
U.S.C. 823(a) and § 952(a) and
determined that the registration of
Mylan Pharmaceuticals Inc., to import
the basic classes of controlled
substances is consistent with the public
interest and with United States
obligations under international treaties,
E:\FR\FM\28OCN1.SGM
28OCN1
55586
Federal Register / Vol. 74, No. 207 / Wednesday, October 28, 2009 / Notices
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Mylan Pharmaceuticals Inc.
to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and § 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic classes of controlled
substances listed.
Dated: October 20, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–25908 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
erowe on DSK5CLS3C1PROD with NOTICES
Importer of Controlled Substances;
Notice of Registration
By Notice dated June 22, 2009, and
published in the Federal Register on
June 29, 2009, (74 FR 31049), Noramco,
Inc., Division of Ortho-McNeil, Inc.,
1440 Olympic Drive, Athens, Georgia
30601, made application by letter to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Tapentadol (9780), a basic class of
controlled substance listed in schedule
II.
The company plans to import an
intermediate of the basic class listed for
the bulk manufacture of Tapentadol
which it will distribute to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Noramco, Inc. to import the basic class
of controlled substance is consistent
with the public interest and with United
States obligations under international
treaties, conventions, or protocols in
effect on May 1, 1971, at this time. DEA
has investigated Noramco, Inc. to ensure
that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and § 958(a), and in accordance with 21
VerDate Nov<24>2008
15:34 Oct 27, 2009
Jkt 220001
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: October 16, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–25906 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on June 18, 2009,
Archimica, Inc., 2460 W. Bennett Street,
Springfield, Missouri 65807–1229, made
application by letter to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Tapentadol (9780), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance in bulk
for distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 28, 2009.
Dated: October 21, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–26003 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Gamma
hydroxybutyric
acid
(2010).
Amphetamine (1100) ....................
Methylphenidate (1724) ................
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 26, 2009,
Lonza Riverside, 900 River Road,
Conshohocken, Pennsylvania 19428,
made application by renewal to the
PO 00000
Frm 00051
Fmt 4703
Sfmt 4703
II
II
Dated: October 16, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. E9–25890 Filed 10–27–09; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application
Pursuant to § 1301.33(a) of Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on March 31, 2009,
Lin Zhi International Inc., 687 North
Pastoria Avenue, Sunnyvale, California
94085, made application by renewal to
the Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic classes of
controlled substances listed in
schedules I and II:
Drug
Manufacturer of Controlled
Substances; Notice of Application
I
The company plans to manufacture
bulk products for finished dosage units
and distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than December 28, 2009.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Schedule
Tetrahydrocannabinols (7370) .....
3,4–Methylenedioxymethamphetamine (MDMA) (7405).
Cocaine (9041) .............................
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
E:\FR\FM\28OCN1.SGM
28OCN1
Schedule
I
I
II
II
II
II
II
II
]]>Agencies
[Federal Register Volume 74, Number 207 (Wednesday, October 28, 2009)]
[Notices]
[Pages 55585-55586]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-25908]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances; Notice of Registration
By Notice dated June 3, 2009, and published in the Federal Register
on June 9, 2009 (74 FR 27349), Mylan Technologies Inc., 110 Lake
Street, Saint Albans, Vermont 05478, made application to the Drug
Enforcement Administration (DEA) to be registered as an importer of the
basic classes of controlled substances listed in schedule II:
------------------------------------------------------------------------
Drug Schedule
------------------------------------------------------------------------
Methylphenidate (1724)...................... II
Fentanyl (9801)............................. II
------------------------------------------------------------------------
The company plans to import the listed controlled substances for
analytical research and clinical trials.
Two objections and one request for a hearing were received. The
request for a hearing has been withdrawn. DEA has examined the other
objections to the registration and has determined that the objections
and comments received are not valid for this specific situation. The
company will import finished dosage forms for clinical trials and
analytical comparison only. They will not purchase raw material for the
manufacture of finished goods and/or commercial distribution. No other
use of the imported material in question will be allowed.
DEA has considered the factors in 21 U.S.C. 823(a) and Sec. 952(a)
and determined that the registration of Mylan Pharmaceuticals Inc., to
import the basic classes of controlled substances is consistent with
the public interest and with United States obligations under
international treaties,
[[Page 55586]]
conventions, or protocols in effect on May 1, 1971, at this time. DEA
has investigated Mylan Pharmaceuticals Inc. to ensure that the
company's registration is consistent with the public interest. The
investigation has included inspection and testing of the company's
physical security systems, verification of the company's compliance
with state and local laws, and a review of the company's background and
history. Therefore, pursuant to 21 U.S.C. 952(a) and Sec. 958(a), and
in accordance with 21 CFR 1301.34, the above named company is granted
registration as an importer of the basic classes of controlled
substances listed.
Dated: October 20, 2009.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. E9-25908 Filed 10-27-09; 8:45 am]
BILLING CODE 4410-09-P
